Of these, the HGF/cMET pathway has seemed an attractive target as it has been shown to operate in many tumors, for example, preclinical studies in glioblastoma [25] and pancreatic neuroendocrine tumor models [32] have shown that MET inhibitors can overcome resistance to anti-VEGF therapy. The gene discussed is HGF; the disease is pancreatic neuroendocrine tumor.